Denali Therapeutics Q4 net loss deepens

Denali Therapeutics

26/02/2026 21:27

Overview

Biotechnology firm reported deeper Q4 net loss of $128.5 mln

Company established launch readiness for tividenofusp alfa for Hunter syndrome

Company announced $275 mln royalty funding agreement and $200 mln public offering

Outlook

Denali expects to launch tividenofusp alfa for Hunter syndrome in April 2026

Company plans to pursue accelerated approval for DNL126 in Sanfilippo syndrome type A

Denali initiates clinical studies for DNL628 in Alzheimer's and DNL952 in Pompe disease

Result Drivers

G&A EXPENSES - Increased to $39.5 mln from $30.1 mln, due to headcount increases and other activities associated with preparing for the potential commercial launch for tividenofusp alfa

Company press release: ID:nGNX8V0VWQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$128.55 mln
Q4 Basic EPS
-$0.73
Q4 Operating Expenses
$137.37 mln
Q4 Operating Income
-$137.37 mln
Q4 Pretax Profit
-$128.45 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Denali Therapeutics Inc is $32.00, about 43.6% above its February 25 closing price of $22.29

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)